AbbVie Inc.

ABBVleader

AbbVie is a global biopharmaceutical company that was spun off from Abbott Laboratories in 2013. While Humira was once the world's best-selling drug, AbbVie has successfully navigated its patent cliff with Skyrizi and Rinvoq, which are on track to exceed Humira's peak revenue combined.

⇄ Compare

Produkte & Umsatz

Umsatzanteil nach Produkt

Umsatzaufschlüsselung ($56.3B)

Statische Daten (Echtzeitfinanzen werden geladen…)

Immunology (45%)

Aesthetics/Neuroscience (25%)

Oncology (15%)

Eye Care & Other (15%)

Segmentzusammensetzung und Hauptkunden

Produktdetails

Skyrizi / Rinvoq35%

Next-generation immunology biologics replacing Humira revenue

Humira20%

Anti-TNF biologic for rheumatoid arthritis and autoimmune diseases (declining post-LOE)

Botox / Aesthetics25%

Allergan aesthetics portfolio including Botox, Juvederm, and CoolSculpting

Lieferkettenbeziehungen

Wettbewerber

Eli Lilly and Company

Immunology and oncology drugs

Auswirkung: Key therapeutic competitor

Regeneron Pharmaceuticals

Dupixent vs Skyrizi/Rinvoq

Auswirkung: Direct immunology competition

Pfizer Inc.

Broad pharmaceutical portfolio overlap

Auswirkung: Major pharma rival

Makro- und Marktkontext

제약 / 바이오Sektornachrichten

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

Nächste Katalysatoren

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

Aktuelle Nachrichten

Nachrichten laden...

KI-Analyse

Klicken Sie auf "KI-Analyse abrufen" für eine KI-gestützte Lieferkettenanalyse von AbbVie Inc..

Unternehmensinformationen

Hauptsitz

North Chicago, Illinois, USA

Gegründet

2013

Mitarbeiter

50,000+

Website

abbvie.com

Sektorübersicht — 제약 / 바이오

Sektornachrichten